No Data
Huisheng Biotech: Report for the third quarter of 2024
Wuhan HVSen Biotechnology (300871.SZ) released its performance for the first three quarters, with a net loss of 47.6583 million yuan.
Wuhan HVSen Biotechnology (300871.SZ) released the third quarter report of 2024, with the company's revenue for the first three quarters reaching 7...
Wuhan HVSen Biotechnology (300871.SZ): a net loss of 47.6583 million yuan in the first three quarters.
Gelonghui October 29th 丨 Wuhan Hvsen Biotechnology (300871.SZ) released the third quarter report of 2024, achieving revenue of 0.793 billion yuan in the first three quarters, a year-on-year increase of 14.63%; net income attributable to shareholders of the listed company was -47.6583 million yuan; net income attributable to shareholders after deducting non-recurring gains and losses was -32.3973 million yuan; basic earnings per share was -0.29 yuan.
Express News | wuhan hvsen biotechnology and others established Shengchong Technology Company in Wuhan.
Wuhan HVSen Biotechnology (300871): Decline in formulation profit combined with losses from private equity investment. Net income attributable to mother in the first half of the year compared to the same period last year.
The main business profit declined, coupled with the loss from private equity investment, and the short-term performance is under significant pressure. The company achieved revenue of 0.436 billion yuan in H1 2024, a year-on-year decrease of 2.85%, of which Q2 achieved revenue of 0.229 billion yuan, a quarter-on-quarter increase of 10%.
Huisheng Biotech: 2024 Semi-Annual Report Summary
No Data
No Data